A Latent DNA–Protein Cross-Link Agent as a Chemical Adjuvant for Photodynamic Therapy
Journal of the American Chemical Society · 2026
DOI: 10.1021/jacs.6c13537 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of the American Chemical Society, 2026. Verfasst von Xuanhe Jiang und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemistry, Johns Hopkins University, 3400 N. Charles St., Baltimore, Maryland21218, United States. Hauptthemen laut MEDLINE: Photochemotherapy, DNA, Cross-Linking Reagents, Photosensitizing Agents. Die Arbeit nennt 95 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIGMS NIH HHS, Associazione Italiana per la Ricerca sul Cancro, Ministero dell'Universit? e della Ricerca.
Abstract (Originalsprache)
Photodynamic therapy (PDT) induces cell death in part through singlet oxygen (1O2)-mediated oxidation of DNA and other biomolecules. However, PDT effectiveness can be compromised in cancer cells by increased capacity for base excision repair (BER) of DNA lesions and/or proteostasis-associated tolerance of oxidative protein damage. We envisioned that using 1O2 to create DNA–protein cross-links (DPCs) would reduce the protective effect of BER overexpression and help overcome cellular PDT-resistance. Here, we describe a furan-containing adjuvant (MCF) that yields DPCs under PDT conditions. As a half-nitrogen mustard, MCF alkylates DNA and subsequently undergoes 1O2-mediated furan oxidation to generate a DNA-tethered 1,4-dicarbonyl electrophile that reacts with protein nucleophiles to form DPCs. MCF-dependent DPC formation was observed in nucleosome core particles and human cells under PDT conditions. DPC formation in NCPs and human cells increased in D2O, consistent with 1O2-mediated oxidation of MCF DNA adducts. DPC levels were also elevated in cells lacking functional SPRTN, a protease involved in DPC repair. Photochemical activation of MCF increased cellular toxicity. This effect was amplified by SPRTN truncation or proteasome inhibition, implicating proteolytic DPC processing in protection from MCF-induced phototoxicity. Importantly, MCF retained its cytotoxic enhancement in cells that overexpress the BER protein APE1. MCF also substantially reduced the detectable survival advantage of a HeLa cell population selected for resistance to PDT conditions. These results support MCF as a latent DPC precursor that potentiates PDT in cells with reduced sensitivity to oxidative photodamage.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Chemistry, Johns Hopkins University, 3400 N. Charles St., Baltimore, Maryland21218, United States.
- Laboratory of Molecular Biology and DNA Repair, Department of Medicine (DMED), University of Udine, Piazzale Massimiliano Kolbe 4, Udine33100, Italy.
ORCID-Profile: Gianluca Tell, Marc M Greenberg
Förderung
- NIGMS NIH HHS
- Associazione Italiana per la Ricerca sul Cancro
- Ministero dell'Universit? e della Ricerca
- Division of Chemistry
Zitieren
APA
Jiang, X., Antoniali, G., Tell, G., & Greenberg, M. M. (2026). A Latent DNA–Protein Cross-Link Agent as a Chemical Adjuvant for Photodynamic Therapy. Journal of the American Chemical Society. https://doi.org/10.1021/jacs.6c13537
Vancouver
Jiang X, Antoniali G, Tell G, Greenberg MM. A Latent DNA–Protein Cross-Link Agent as a Chemical Adjuvant for Photodynamic Therapy. Journal of the American Chemical Society. 2026. doi:10.1021/jacs.6c13537
BibTeX
@article{Jiang2026,
author = {Jiang, Xuanhe and Antoniali, Giulia and Tell, Gianluca and Greenberg, Marc M},
title = {A Latent DNA–Protein Cross-Link Agent as a Chemical Adjuvant for Photodynamic Therapy},
journal = {Journal of the American Chemical Society},
year = {2026},
doi = {10.1021/jacs.6c13537}
}
EUVIMED